Newsroom

Sorted by: Latest

-

The OpenFold Consortium Names Dr. Jan Domanski as Senior Science Lead to Drive the Next Generation of Open Source AI Models for Structural Biology and Drug Discovery

DAVIS, Calif.--(BUSINESS WIRE)--Dr. Domanski embodies the spirit of OpenFold: a deep scientific understanding of proteins with engineering expertise and a builder’s mindset...
-

Atelerix Enters Agreement with Cherry Biotech to Integrate Non-cryogenic Transport Solutions With Advanced Organoid Models

NEWCASTLE, England--(BUSINESS WIRE)--Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced it has entered a partnership with Cherry Biotech, a French company specialising in organ-on-chip and organoid technologies for biomedical research. The initial agreement will explore the integration of Atelerix’s patented hydrogel technology with Cherry Biotech’s advanced 3D organoid models to facilitat...
-

TimesSquare Capital Management, LLC UK Regulatory Announcement: Form 8.3

NEW YORK--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: TimesSquare Capital Management, LLC (“TimesSquare”) (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor an...
-

Havas Reports the Progress of Transactions Under Its Current Share Buyback Program

PARIS--(BUSINESS WIRE)--Havas reports the progress of transactions under its current share buyback program....
-

River Global Investors LLP UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: River Global Investors LLP 213800HIGHFCAY9K8Z97 (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and bene...
-

CRH plc UK Regulatory Announcement: Transaction in Own Shares

NEW YORK--(BUSINESS WIRE)--  15th December 2025 CRH plc Transaction in Own Shares CRH plc (“CRH”) announces that on 12th December 2025 it acquired the following number of its ordinary shares (the “ordinary shares”) in the United States through CRH’s broker Santander US Capital Markets LLC. The ordinary shares acquired (by way of redemption) will be cancelled. Aggregate number of ordinary shares acquired Daily volume weighted average price paid Daily highest price paid per share Daily lowest pri...
-

Marathon Asset Management Ltd UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Marathon Asset Management Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must...
-

GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe

ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma partners with Otsuka Pharmaceutical Europe Ltd. to commercialize donidalorsen for hereditary angioedema in Central & Eastern Europe....
-

FinQuery Accelerates Momentum With 19th Consecutive Quarter as the Top-Ranked Lease Accounting Software

LONDON--(BUSINESS WIRE)--FinQuery Accelerates Momentum With 19th Consecutive Quarter as the Top-Ranked Lease Accounting Software...
-

LEO Pharma Submits Adolescent Label Expansion Application for Anzupgo® to EMA

BALLERUP, Denmark--(BUSINESS WIRE)--NOT FOR UK USE – NOT INTENDED FOR UK MEDIA LEO Pharma A/S, a global leader in medical dermatology, today announced submission of a label expansion application to the European Medicines Agency (EMA) to expand the use of Anzupgo® (delgocitinib) cream to adolescents aged 12 to 17 years, living with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate in the European Union. The label expansion application h...